1
|
Chatterjee T, Ravichandran N, Nair N, Gracia‐Ramos AE, Barman B, Sen P, Joshi M, Saha S, Nune A, Pande AKR, Velikova T, Parodis I, Tan AL, Shinjo SK, Boro H, Agarwal V, Aggarwal R, Gupta L. Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD study. J Diabetes Investig 2024; 15:131-138. [PMID: 37697820 PMCID: PMC10759717 DOI: 10.1111/jdi.14079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2023] [Revised: 08/16/2023] [Accepted: 08/20/2023] [Indexed: 09/13/2023] Open
Abstract
AIMS/INTRODUCTION Coronavirus disease 2019 (COVID-19) vaccinations have been proven to be generally safe in healthy populations. However, the data on vaccine safety in patients with type 1 diabetes are scarce. This study aimed to evaluate the frequency and severity of short-term (<7-day) adverse vaccination events (AEs) and their risk factors among type 1 diabetes patients. MATERIALS AND METHODS This study analyzed data from the COVID-19 vaccination in Autoimmune Diseases (COVAD) survey database (May to December 2021; 110 collaborators, 94 countries), comparing <7-day COVID-19 vaccine AE among type 1 diabetes patients and healthy controls (HCs). Descriptive statistics; propensity score matching (1:4) using the variables age, sex and ethnicity; and multivariate analyses were carried out. RESULTS This study analyzed 5,480 completed survey responses. Of all responses, 5,408 were HCs, 72 were type 1 diabetes patients (43 females, 48.0% white European ancestry) and Pfizer was the most administered vaccine (39%). A total of 4,052 (73.9%) respondents had received two vaccine doses. Patients with type 1 diabetes had a comparable risk of injection site pain, minor and major vaccine AEs, as well as associated hospitalizations to HCs. However, type 1 diabetes patients had a higher risk of severe rashes (3% vs 0.4%, OR 8.0, 95% confidence interval 1.7-36), P = 0.007), although reassuringly, these were rare (n = 2 among type 1 diabetes patients). CONCLUSIONS COVID-19 vaccination was safe and well tolerated in patients with type 1 diabetes with similar AE profiles compared with HCs, although severe rashes were more common in type 1 diabetes patients.
Collapse
Affiliation(s)
- Tulika Chatterjee
- Department of Internal Medicine, Center for Outcomes ResearchUniversity of Illinois College of Medicine PeoriaPeoriaIllinoisUSA
| | - Naveen Ravichandran
- Department of Clinical Immunology and RheumatologySanjay Gandhi Postgraduate Institute of Medical SciencesLucknowIndia
| | - Narmadha Nair
- Department of EndocrinologyRoyal Wolverhampton Hospitals NHS TrustWolverhamptonUK
| | - Abraham Edgar Gracia‐Ramos
- Department of Internal Medicine, National Medical Center “La Raza”, Instituto Mexicano del Seguro SocialGeneral HospitalMexico CityMexico
| | - Bhupen Barman
- Department of MedicineAll India Institute of Medical Science (AIIMS)GuwahatiIndia
| | | | - Mrudula Joshi
- Byramjee Jeejeebhoy Government Medical College and Sassoon General HospitalsPuneIndia
| | | | - Arvind Nune
- Department of RheumatologySouthport and Ormskirk Hospital NHS TrustSouthportUK
| | | | | | - Ioannis Parodis
- Division of Rheumatology, Department of Medicine Solna, Karolinska InstitutetKarolinska University HospitalStockholmSweden
- Department of Rheumatology, Faculty of Medicine and HealthÖrebro UniversityÖrebroSweden
| | - Ai Lyn Tan
- NIHR Leeds Biomedical Research CentreLeeds Teaching Hospitals TrustLeedsUK
- Leeds Institute of Rheumatic and Musculoskeletal MedicineUniversity of LeedsLeedsUK
| | - Samuel Katsuyuki Shinjo
- Division of Rheumatology, Faculdade de Medicina FMUSPUniversidade de Sao PauloSao PauloBrazil
| | - Hiya Boro
- Department of Endocrinology and MetabolismAll India Institute of Medical SciencesNew DelhiIndia
| | - Vikas Agarwal
- Department of Clinical Immunology and RheumatologySanjay Gandhi Postgraduate Institute of Medical SciencesLucknowIndia
| | - Rohit Aggarwal
- Division of Rheumatology and Clinical ImmunologyUniversity of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | - Latika Gupta
- Department of RheumatologyRoyal Wolverhampton Hospitals NHS TrustWolverhamptonUK
- Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine, and Health, Centre for Musculoskeletal Research, Manchester Academic Health Science CentreThe University of ManchesterManchesterUK
- Sandwell and West Birmingham Hospitals NHS TrustCity HospitalBirminghamUK
| |
Collapse
|
2
|
Gil‐Vila A, Naveen R, Selva‐O'Callaghan A, Sen P, Nune A, Gaur PS, Gonzalez RA, Lilleker JB, Joshi M, Agarwal V, Kardes S, Kim M, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia‐Ramos AE, Parodis I, Nikiphorou E, Tan AL, Chatterjee T, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L, Barman B, Singh YP, Ranjan R, Jain A, Pandya SC, Pilania RK, Sharma A, Manesh Manoj M, Gupta V, Kavadichanda CG, Patro PS, Ajmani S, Phatak S, Goswami RP, Chowdhury AC, Mathew AJ, Shenoy P, Asranna A, Bommakanti KT, Shukla A, Pandey AKR, Chandwar K, Cansu DÜ, Pauling JD, Wincup C, Del Papa N, Sambataro G, Fabiola A, Govoni M, Parisi S, Bocci EB, Sebastiani GD, Fusaro E, Sebastiani M, Quartuccio L, Franceschini F, Sainaghi PP, Orsolini G, De Angelis R, Danielli MG, Venerito V, Traboco LS, Wibowo SAK, Tehozol EAZ, Serrano JR, La Torre IG, Loarce‐Martos J, Prieto‐González S, Gil‐Vila A, Gonzalez RA, Yoshida A, Nakashima R, Sato S, Kimura N, Kaneko Y, Tomaras S, Gromova MA, Aharonov O, Hmamouchi I, Hoff LS, Giannini M, Maurier F, Campagne J, Meyer A, Nagy‐Vincze M, Langguth D, Limaye V, Needham M, Srivastav N, Hudson M, Landon‐Cardinal O, Shaharir SS, Zuleta WGR, Silva JAP, Fonseca JE, Zimba O. COVID‐19 Vaccination In Autoimmune Diseases (COVAD) Study: Vaccine Safety In Idiopathic Inflammatory Myopathies. Muscle Nerve 2022; 66:426-437. [PMID: 35869701 PMCID: PMC9349921 DOI: 10.1002/mus.27681] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 07/09/2022] [Accepted: 07/17/2022] [Indexed: 11/30/2022]
Abstract
Introduction/Aims In this study we investigated COVID‐19 vaccination–related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs). Methods Seven‐day vaccine ADEs were collected in an international patient self‐reported e‐survey. Descriptive statistics were obtained and multivariable regression was performed. Results Ten thousand nine hundred respondents were analyzed (1227 IIM cases, 4640 SAID cases, and 5033 healthy controls [HCs]; median age, 42 [interquartile range, 30‐455] years; 74% female; 45% Caucasian; 69% completely vaccinated). Major ADEs were reported by 76.3% of the IIM patients and 4.6% reported major ADEs. Patients with active IIMs reported more frequent major (odds ratio [OR], 2.7; interquartile range [IQR], 1.04‐7.3) and minor (OR, 1.5; IQR, 1.1‐2.2) ADEs than patients with inactive IIMs. Rashes were more frequent in IIMs (OR, 2.3; IQR, 1.2‐4.2) than HCs. ADEs were not impacted by steroid dose, although hydroxychloroquine and intravenous/subcutaneous immunoglobulins were associated with a higher risk of minor ADEs (OR, 1.9; IQR, 1.1‐3.3; and OR, 2.2; IQR, 1.1‐4.3, respectively). Overall, ADEs were less frequent in inclusion‐body myositis (IBM) and BNT162b2 (Pfizer) vaccine recipients. Discussion Seven‐day postvaccination ADEs were comparable in patients with IIMs, SAIDs, and HCs, except for a higher risk of rash in IIMs. Patients with dermatomyositis with active disease may be at higher risk, and IBM patients may be at lower risk of specific ADEs. Overall, the benefit of preventing severe COVID‐19 through vaccination likely outweighs the risk of vaccine‐related ADEs. Our results may inform future guidelines regarding COVID‐19 vaccination in patients with SAIDs, specifically in those with IIMs. Studies to evaluate long‐term outcomes and disease flares are needed to shed more light on developing future COVID‐19 vaccination guidelines.
Collapse
Affiliation(s)
- Albert Gil‐Vila
- Systemic Autoimmune Diseases Unit, Vall d'Hebron General Hospital, Medicine Dept Universitat Autónoma de Barcelona Barcelona Spain
| | - R. Naveen
- Department of Clinical Immunology and Rheumatology Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India
| | - Albert Selva‐O'Callaghan
- Systemic Autoimmune Diseases Unit, Vall d'Hebron General Hospital, Medicine Dept Universitat Autónoma de Barcelona Barcelona Spain
| | - Parikshit Sen
- Maulana Azad Medical College, 2‐Bahadurshah Zafar Marg, New Delhi Delhi India
| | - Arvind Nune
- Southport and Ormskirk Hospital NHS Trust Southport UK
| | | | - Raquel Arànega Gonzalez
- Internal Medicine Department Hospital Clinic, Consorci Sanitari del Maresme, Mataró Barcelona Spain
| | - James B. Lilleker
- Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre The University of Manchester Manchester UK
- Neurology, Manchester Centre for Clinical Neurosciences Northern Care Alliance NHS Foundation Trust Salford UK
| | - Mrudula Joshi
- Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals Pune India
| | - Vishwesh Agarwal
- Mahatma Gandhi Mission Medical College Navi Mumbai Maharashtra India
| | - Sinan Kardes
- Department of Medical Ecology and Hydroclimatology, Istanbul Faculty of Medicine Istanbul University, Capa‐Fatih Istanbul Turkey
| | - Minchul Kim
- Center for Outcomes Research, Department of Internal Medicine University of Illinois College of Medicine Peoria Illinois USA
| | - Jessica Day
- Department of Rheumatology Royal Melbourne Hospital Parkville VIC Australia
- Walter and Eliza Hall Institute of Medical Research Parkville VIC Australia
- Department of Medical Biology University of Melbourne Parkville VIC Australia
| | - Ashima Makol
- Division of Rheumatology Mayo Clinic Rochester MN USA
| | - Marcin Milchert
- Department of Internal Medicine, Rheumatology, Geriatrics and Clinical Immunology Pomeranian Medical University in Szczecin, ul Unii Lubelskiej 1 Szczecin Poland
| | - Tamer Gheita
- Rheumatology Department, Kasr Al Ainy School of Medicine Cairo University Cairo Egypt
| | - Babur Salim
- Rheumatology Department Fauji Foundation Hospital Rawalpindi Pakistan
| | - Tsvetelina Velikova
- Department of Clinical Immunology, Medical Faculty University Hospital "Lozenetz", Sofia University St. Kliment Ohridski, 1 Kozyak Str. Sofia Bulgaria
| | - Abraham Edgar Gracia‐Ramos
- Department of Internal Medicine, General Hospital National Medical Center “La Raza”, Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P Mexico City Mexico
| | - Ioannis Parodis
- Division of Rheumatology, Department of Medicine Solna Karolinska Institutet and Karolinska University Hospital Stockholm Sweden
- Department of Rheumatology, Faculty of Medicine and Health Örebro University Örebro Sweden
| | - Elena Nikiphorou
- Centre for Rheumatic Diseases King's College London London UK
- Rheumatology Department King's College Hospital London UK
| | - Ai Lyn Tan
- NIHR Leeds Biomedical Research Centre Leeds Teaching Hospitals Trust Leeds UK
- Leeds Institute of Rheumatic and Musculoskeletal Medicine University of Leeds Leeds UK
| | - Tulika Chatterjee
- Center for Outcomes Research, Department of Internal Medicine University of Illinois College of Medicine Peoria Illinois USA
| | - Lorenzo Cavagna
- Department of Rheumatology Fondazione I.R.C.C.S. Policlinico San Matteo Pavia Italy
- Rheumatology Unit, Dipartimento di Medicine Interna e Terapia Medica Università degli studi di Pavia Pavia Lombardy Italy
| | - Miguel A. Saavedra
- Departamento de Reumatología Hospital de Especialidades Dr. Antonio Fraga Mouret Centro Médico Nacional La Raza, IMSS Mexico City Mexico
| | - Samuel Katsuyuki Shinjo
- Division of Rheumatology, Faculdade de Medicina FMUSP Universidade de Sao Paulo, Sao Paulo SP Brazil
| | - Nelly Ziade
- Rheumatology Department Saint‐Joseph University Beirut Lebanon
- Rheumatology Department Hotel‐Dieu de France Hospital Beirut Lebanon
| | - Johannes Knitza
- Medizinische Klinik 3 ‐ Rheumatologie und Immunologie Universitätsklinikum Erlangen, Friedrich‐Alexander‐Universität Erlangen‐Nürnberg, Ulmenweg 18 Erlangen Deutschland
| | - Masataka Kuwana
- Department of Allergy and Rheumatology Nippon Medical School Graduate School of Medicine, 1‐1‐5 Sendagi, Bunkyo‐ku Tokyo Japan
| | - Oliver Distler
- Department of Rheumatology University Hospital Zurich, University of Zurich Zurich Switzerland
| | - Hector Chinoy
- Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre The University of Manchester Manchester UK
- National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust The University of Manchester Manchester UK
- Department of Rheumatology Salford Royal Hospital Northern Care Alliance NHS Foundation Trust Salford UK
| | - Vikas Agarwal
- Department of Clinical Immunology and Rheumatology Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India
| | - Rohit Aggarwal
- Division of Rheumatology and Clinical Immunology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA
| | - Latika Gupta
- Department of Clinical Immunology and Rheumatology Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India
- Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre The University of Manchester Manchester UK
- Dept of Rheumatology Royal Wolverhampton Hospital NHS Trust Wolverhampton United Kingdom
- City Hospital, Sandwell and West Birmingham Hospitals NHS Trust Birmingham United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|